BSE filing, NSE: ZIMLAB. Summary written from the filing by ALFA Finder's alert engine.
Zim Laboratories Ltd: key numbers
- Share price
- ₹134.00
- Market cap
- ₹719.0 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 194.5×Sector 46.1×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Other board meeting date announcements
All →HMT Board Meeting Date
HMT Ltd will hold a board meeting on 6 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The notice is advance intimation only.
Svarnim Trade Udyog Board Meeting Date
Svarnim Trade Udyog will hold a board meeting on 3 November 2026 to consider unaudited quarterly and half-year results. No amounts are stated.
Intrasoft Technologies Board Meeting Date
Intrasoft Technologies will hold a board meeting on 06-Nov-2026 to consider unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026. Trading window remains closed until 48 hours after the meeting.
Ruparel Food Products Board Meeting Date
Ruparel Food Products will hold a board meeting on 02-Nov-2026 to consider unaudited standalone and consolidated half-yearly financial results for September 2026. Trading window is closed from 01-Oct-2026.
Accedere Board Meeting Date
Accedere Limited intimated a board meeting on 4 November 2026 to consider its unaudited Q2 standalone and consolidated results. Trading window closure is also noted, so this is a future meeting notice.
Systematic Industries Board Meeting Date
Systematic Industries Limited intimates a board meeting on November 3, 2026, to consider unaudited standalone results for the half year ended September 30, 2026. The trading window is closed from October 1, 2026 until 48 hours after the results are declared.